Ophthalmology Product Guide

Alcon Buys Rights For Durezol and Zirgan

Jim Marino — Thu, 28 Jan 2010 05:07:18 +0000

Alcon has bought rights for and Zirgan from Sirion Therapeutics Inc. for an undisclosed amount. While Durezol is an ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, Zirgan is an antiviral for the treatment of corneal ulcers. Both products have been approved by the Food and Drug Administration.

Alcon said it has acquired the global rights, excluding Latin America, for Zyclorin, which is being developed as a potential treatment for dry eyes and other diseases.

Alcon Buys Rights For Durezol and Zirgan

Alcon has bought rights for Durezol and Zirgan from Sirion Therapeutics Inc. for an undisclosed amount. While Durezol is an ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, Zirgan is an antiviral for the treatment of corneal ulcers. Both products have been approved by the Food and Drug Administration.

Alcon said it has acquired the global rights, excluding Latin America, for Zyclorin, which is being developed as a potential treatment for dry eyes and other diseases.

Alcon To Purchase Ophthalmic Pharmaceutical Assets From Sirion

Jim Marino — Fri, 22 Jan 2010 04:21:42 +0000

Alcon has announced that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).

For the full story, Click Here

Cornea Cell Density Predictive Of Graft Failure Post Transplant

Jim Marino — Thu, 14 Jan 2010 07:43:07 +0000

A new predictor of cornea transplant success has been identified by the Cornea Donor Study (CDS) Investigator Group. New analysis of data from the 2008 Specular Microscopy Ancillary Study, found that the preoperative donor cell count of endothelial cells, did not correlate with graft success. Instead the study found that a patient’s endothelial cell count six months post-cornea transplant is a better indicator of subsequent failure of the graft rather than the donor’s cell count.

For the full story, Click Here

Icon Bioscience Initiates Phase 2/3 Pivotal Clinical Study Of Novel Ophthalmic Drug Candidate

Jim Marino — Fri, 08 Jan 2010 12:37:01 +0000

Icon Bioscience, Inc. has announced that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery. IBI-10090 is a novel anti-inflammatory drug product, based on IBI’s proprietary Verisome(TM) drug delivery platform technology, administered as a single injection into the anterior chamber of the eye that is designed to last approximately two to three weeks.

For the full story, Click Here

Avedro Initiates Keraflex(R) KXL Clinical Trials For Treating Keratoconus

Jim Marino — Wed, 30 Dec 2009 12:00:41 +0000

During the 5th International Congress of Corneal Cross Linking for Keratoconus in Germany, Avedro presented encouraging clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue. Keratoconus, or KC, is a cone-shaped protrusion and distortion of the cornea that typically begins in the teenage years or 20’s and afflicts millions of people around the world.

For the full story, Click Here

Study links hydrogel contact lens types and solutions to adverse events

Jim Marino — Thu, 24 Dec 2009 05:36:39 +0000

Use of hydrogen peroxide solution was associated with the lowest incidence of corneal infiltration among daily hydrogel contact lens wearers, according to a study published in Arch Ophthalmol. The study included 558 patients with myopia who participated in one or more of about 40 trials for 20 hydrogel contact lens and lens solution combinations. Patient assessments were conducted at baseline, 2 weeks, 1 month and 3 months. Data included 840 lens-solution combinations and 2,271 participant-months.

For the full story, Click Here

Paradigm Medical Announces the Introduction of the Paravue 300 and Surveyor 500

Jim Marino — Thu, 17 Dec 2009 05:15:01 +0000

Paradigm Medical Industries, Inc. announced that it introduced two new products at the annual American Academy of Ophthalmology Meeting in San Francisco. The new products consisted of the Paravue 300, a corneal topographer, and the Surveyor 500, a fully capable corneal topographer with a Scheimpflug technology rotating camera for the measurement of interior ocular structures in the anterior segment.

For the full story here, Click Here

Aston University researchers receive funds to study fundamental processes of human vision

Jim Marino — Thu, 10 Dec 2009 13:28:29 +0000

Researchers at Aston University, UK have been awarded over £1 million pounds worth of funding from the BBSRC and the EPSRC to investigate the fundamental processes involved in human vision. The BBSRC project will see the Aston research team conduct psychophysical experiments to study the binocular perception and performance of human observers in order to develop a more complete theory and understanding of binocular spatial vision through successive refinements of a computational model.

Multicenter Study Finds AMD Patients Benefit from Cataract Surgery

Jim Marino — Thu, 03 Dec 2009 11:26:59 +0000

Cataract surgery improved vision in patients with any stage–from mild to advanced– AMD in the first study to include an adequate number of advanced AMD patients. Data was obtained from the multicenter, prospective Age-Related Eye Disease Study (AREDS), funded by the National Eye Institute (NEI), which was organized primarily to evaluate the effects of high-dose vitamin and mineral supplements on cataract and AMD.

Six-Month Neuroadaptation Period Found for Tecnis Multifocal IOL

Jim Marino — Thu, 26 Nov 2009 15:19:06 +0000

Abbott Medical Optics conducted a 250-eye study of the Tecnis multifocal intraocular lens (IOL) and measured results at three days, 30 days, 90 days, 150 days and 210 days after cataract surgery. Most of the study participants achieved their best vision after 180 days, which the researchers called a neuroadaptation period. During the last checkup, 96.8 percent of eyes could read at 20/20 (J2) without correction, with 83.2 percent reading at 20/15 (J1).